Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.

CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
Marc RodgerMichael J Kovacs

Abstract

Whether to continue oral anticoagulant therapy beyond 6 months after an "unprovoked" venous thromboembolism is controversial. We sought to determine clinical predictors to identify patients who are at low risk of recurrent venous thromboembolism who could safely discontinue oral anticoagulants. In a multicentre prospective cohort study, 646 participants with a first, unprovoked major venous thromboembolism were enrolled over a 4-year period. Of these, 600 participants completed a mean 18-month follow-up in September 2006. We collected data for 69 potential predictors of recurrent venous thromboembolism while patients were taking oral anticoagulation therapy (5-7 months after initiation). During follow-up after discontinuing oral anticoagulation therapy, all episodes of suspected recurrent venous thromboembolism were independently adjudicated. We performed a multivariable analysis of predictor variables (p < 0.10) with high interobserver reliability to derive a clinical decision rule. We identified 91 confirmed episodes of recurrent venous thromboembolism during follow-up after discontinuing oral anticoagulation therapy (annual risk 9.3%, 95% CI 7.7%-11.3%). Men had a 13.7% (95% CI 10.8%-17.0%) annual risk. There was no combinat...Continue Reading

References

Sep 26, 1985·The New England Journal of Medicine·J H WassonL Goldman
Jul 1, 1996·Annals of Internal Medicine·P PrandoniM H Prins
Feb 12, 1997·JAMA : the Journal of the American Medical Association·A LaupacisI G Stiell
Sep 4, 1997·The New England Journal of Medicine·UNKNOWN Columbus InvestigatorsR Baildon
Feb 18, 1998·JAMA : the Journal of the American Medical Association·J D DouketisJ S Ginsberg
Aug 19, 2000·The New England Journal of Medicine·P A KyrleS Eichinger
Jul 21, 2001·The New England Journal of Medicine·G AgnelliUNKNOWN Warfarin Optimal Duration Italian Trial Investigators
Dec 18, 2002·Annals of Internal Medicine·Paolo PrandoniAntonio Girolami
Feb 26, 2003·The New England Journal of Medicine·Paul M RidkerUNKNOWN PREVENT Investigators
Jul 2, 2003·Annals of Internal Medicine·Giancarlo AgnelliUNKNOWN Warfarin Optimal Duration Italian Trial Investigators
Aug 15, 2003·The New England Journal of Medicine·Clive KearonUNKNOWN Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators
Aug 28, 2003·JAMA : the Journal of the American Medical Association·Sabine EichingerPaul A Kyrle
Sep 26, 2003·The New England Journal of Medicine·Philip S WellsMichael J Kovacs
Dec 20, 2005·Journal of Thrombosis and Haemostasis : JTH·M StainS Eichinger
Oct 27, 2006·The New England Journal of Medicine·Gualtiero PalaretiUNKNOWN PROLONG Investigators
Oct 2, 2007·Journal of Thrombosis and Thrombolysis·Giancarlo Agnelli, Cecilia Becattini
Jul 10, 2008·Thrombosis and Haemostasis·Marc A RodgerMichael J Kovacs

❮ Previous
Next ❯

Citations

Jan 29, 2014·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Susan R KahnAndrew Hirsch
Apr 15, 2014·QJM : Monthly Journal of the Association of Physicians·J Thachil
Jul 6, 2014·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Saurabh SaigalDinesh Kumar Singh
Jun 25, 2013·Blood Reviews·P L den ExterF A Klok
Jan 10, 2014·Journal of Thrombosis and Thrombolysis·Ashfaque A MemonBengt Zöller
Aug 30, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Clive Kearon
Feb 26, 2011·BMJ : British Medical Journal·James DouketisAlfonso Iorio
May 25, 2012·International Journal of Critical Illness and Injury Science·Sanjith Saseedharan, Sunil Bhargava
Mar 2, 2013·Seminars in Interventional Radiology·Raj S Kasthuri, Nigel S Key
Jan 25, 2013·Current Treatment Options in Cardiovascular Medicine·Maura MarcucciJames Douketis
Feb 18, 2011·Journal of Thrombosis and Thrombolysis·Marco P Donadini, Walter Ageno
Aug 31, 2010·Der Internist·J HarenbergM Wehling
Aug 6, 2013·Current Opinion in Pulmonary Medicine·Daniela Poli, Gualtiero Palareti
May 22, 2009·Current Opinion in Pulmonary Medicine·Richard H White, Susan Murin
Oct 14, 2009·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Ralf LehmannIoakim Spyridopoulos
Aug 5, 2015·Blood Reviews·David KeelingGrégoire Le Gal
Dec 15, 2015·Blood·Paul A Kyrle
Sep 4, 2015·Journal of Thrombosis and Haemostasis : JTH·Jean-Philippe GalanaudJean-Luc Bosson
May 28, 2014·Thrombosis Research·Paul A Kyrle
Oct 2, 2015·Thrombosis and Haemostasis·M BruzeliusJ Odeberg
Feb 25, 2015·Thrombosis Research·Walter AgenoUNKNOWN RIETE investigators
Jan 1, 2014·Journal of Vascular Surgery. Venous and Lymphatic Disorders·Christopher R LattimerGeorge Geroulakos
Feb 27, 2016·Journal of the American College of Cardiology·Stavros V KonstantinidesGuy Meyer
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·John A HeitRichard H White
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·Scott M StevensJames D Douketis
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·Michael B StreiffJack Ansell
Sep 22, 2012·Medicina clínica·José María Calvo Romero
Sep 4, 2012·Thrombosis Research·Aurélien DellucKarine Lacut

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.